SCHEMBL1734028

SCHEMBL1734028

Cc1cc(NC(=O)CN2CCN(c3ccc(C(F)(F)F)cc3)CC2)ccc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.61
POLB P06746 2/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA7 P43166 1/20 0.61
LMNA P02545 4/20 0.59
ALDH1A1 P00352 3/20 0.59
KDM4E B2RXH2 1/20 0.56
TP53 P04637 1/20 0.56
CETP P11597 1/20 0.55
DEGS1 O15121 1/20 0.54
ALOX15 P16050 1/20 0.53
DRD4 P21917 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ATM Q13315 1/20 0.53
TSHR P16473 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13677005 0.85 CA1 (0.71) MAPTPOLBCA1CA2CA7
Hydrochloric Acid SCHEMBL1736301 0.84 CA1 (0.70) MAPTPOLBCA1CA2CA7
SCHEMBL1734029 0.80 TSHR (0.74) MAPTPOLBCA1CA2CA7
SCHEMBL18657836 0.76 MAPT (1.00) MAPTPOLBLMNAALDH1A1KDM4E
SCHEMBL12508777 0.75 ENPP2 (0.59) MAPTPOLBCA1CA2CA7
SCHEMBL1735145 0.74 CETP (0.69) CA1CA2CA7CETP
SCHEMBL1734846 0.74 CETP (0.79) CETP
SCHEMBL13677247 0.74 CETP (0.79) CA1CA2CA7CETP
SCHEMBL1736275 0.74 CETP (0.75) POLBCA1CA2CA7CETP
SCHEMBL20271782 0.73 CA2 (0.57) MAPTPOLBCA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1954287-B2 CETP INHIBITORS MERCK SHARP & DOHME (US) 2016-02-24 EP disclosed
US-8334290-B2 CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2012-12-18 US disclosed
EP-1954287-B1 CETP INHIBITORS MERCK SHARP & DOHME (US) 2011-11-16 EP disclosed
US-20110262658-A1 PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS ZOPPAS MATTEO 2011-10-27 US disclosed
US-20090264405-A1 Cetp Inhibitors MERCK SHARP & DOHME LLC 2009-10-22 US disclosed
EP-1954287-A2 CETP INHIBITORS Merck & Co., Inc. (US) 2008-08-13 EP disclosed
WO-2007070173-A2 CETP INHIBITORS MERCK & CO., INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264405-A1 Cetp Inhibitors CETP, APOB, PCSK9 MAPT 1796/4885POLB 1635/4885CA1 4788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.